Xiaobing Li

Xiaobing Li, PhD, MBA has a wealth of experience in the pharmaceutical industry. Xiaobing began their career in 1996 at The Janssen Pharmaceutical Companies of Johnson & Johnson, where they served as Director, Compound Development Team Program Management Leader and Team Leader / Drug Discovery from 1999-2005. In 2010, they joined Alkermes as Global Program Leader for ARISTADA and Program Director for Schizophrenia Franchis, where they led the global program team and drove all aspects of product development of ARISTADA, long-acting injectable for treatment of schizophrenia. In 2014, they moved to Ironwood Pharmaceuticals as Senior Director, Global Program Leader for Linzess and GCC Platform, where they led global alliance program teams focusing on R&D and lifecycle strategy development & implementation. In 2016, they joined Sage Therapeutics as Senior Director, Global Program Leader for Zulresso (Brexanolone), providing executive program leadership for cross-functional development teams and driving the efficient advancement of high complexity global product development assets from product inception through commercialization of multiple indications in various therapeutic areas. In 2018, they became Vice President, Head of Program Leadership and Portfolio Management at Voyager Therapeutics, Inc., a clinical-stage gene therapy company. In 2020, they moved to Clover Biopharmaceuticals as Chief Portfolio Officer and Executive Vice President, Head of Product Development and Portfolio Strategy. Currently, they are Chief Development Officer at Rectify Pharma.

Xiaobing Li holds a Ph.D. in Heterocyclic/Organic Chemistry from Princeton University and an MBA from Colorado State University.